{
  "meta": {
    "title": "17_Arthropod-Borne_Infections",
    "url": "https://brainandscalpel.vercel.app/17-arthropod-borne-infections-d133d815.html",
    "scrapedAt": "2025-11-30T12:26:54.991Z"
  },
  "questions": [
    {
      "text": "Which malarial parasite has the shortest incubation period?",
      "choices": [
        {
          "id": 1,
          "text": "P. vivax"
        },
        {
          "id": 2,
          "text": "P. malariae"
        },
        {
          "id": 3,
          "text": "P. ovale"
        },
        {
          "id": 4,
          "text": "P. falciparum"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong><em>Plasmodium falciparum</em></strong> has the <strong>shortest</strong> incubation period of<strong> 12 days</strong>.</p><hr><h3>Related Pearl: Difference between plasmodium species</h3><table>\n<tbody>\n<tr>\n<td><strong>Feature</strong></td>\n<td><strong>P.vivax</strong></td>\n<td><strong>P.ovale</strong></td>\n<td><strong>P.falciparum</strong></td>\n<td><strong>P.malaria</strong></td>\n</tr>\n<tr>\n<td>Discovered by</td>\n<td>Grassi &amp; Feletti</td>\n<td>Stephens</td>\n<td>Welch</td>\n<td>Laveran</td>\n</tr>\n<tr>\n<td>Erythrocyte preference</td>\n<td>Reticulocytes</td>\n<td>Reticulocytes</td>\n<td>All stages</td>\n<td>Old erythrocytes</td>\n</tr>\n<tr>\n<td>Stages found in peripheral blood</td>\n<td>Trophozoite, schizonts, gametocytes</td>\n<td>As in vivax</td>\n<td>Ring form, accole form, gametocytes</td>\n<td>Band forms</td>\n</tr>\n<tr>\n<td>Infected erythrocyte</td>\n<td>Enlarged pale with Schuffner’s dots</td>\n<td>Pear-shaped, fimbriated, Schuffner’s dots (Jame’s dots)</td>\n<td>Normal size, Maurer’s cleft</td>\n<td>Normal size, Ziemann’s stippling</td>\n</tr>\n<tr>\n<td>Gametocyte</td>\n<td>Spherical, fills the cell</td>\n<td>Similar to but smaller than vivax</td>\n<td>Crescent, Banana shaped</td>\n<td>Similar to but smaller than vivax</td>\n</tr>\n<tr>\n<td>Color of pigment</td>\n<td>Yellowish-brown</td>\n<td>Yellowish-brown</td>\n<td>Black</td>\n<td>Dark brown</td>\n</tr>\n<tr>\n<td>Hypnozoites</td>\n<td>Present</td>\n<td>Present</td>\n<td>Absent</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td>Relapse</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Average IP(days)</td>\n<td>14</td>\n<td>14</td>\n<td>12 (shortest)</td>\n<td>30 (longest)</td>\n</tr>\n<tr>\n<td>Duration of erythrocyte cycle(hours)</td>\n<td>48 (Benign tertian)</td>\n<td>48 (ovale tertian)</td>\n<td>48 (malignant tertian)</td>\n<td>72(Quartan malaria)</td>\n</tr>\n<tr>\n<td>Others</td>\n<td> </td>\n<td> </td>\n<td> </td>\n<td>Nephrotic syndrome</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8031",
      "difficulty": "medium"
    },
    {
      "text": "A patient from a hilly area was diagnosed with malaria. Which vector is most likely responsible for this?",
      "choices": [
        {
          "id": 1,
          "text": "Anopheles stephensi"
        },
        {
          "id": 2,
          "text": "Anopheles fluviatilis"
        },
        {
          "id": 3,
          "text": "Anopheles culicifacies"
        },
        {
          "id": 4,
          "text": "Anopheles sundaicus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><em><strong>Anopheles fluviatilis</strong></em> is the vector for transmitting malaria in <strong>hilly areas, forests </strong>and<strong> forest fringes.</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Vector</strong></p>\n</td>\n<td>\n<p><strong>Area</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>Anopheles stephensi</em></p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Urban</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>Anopheles culicifacies</em></p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Rural</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>Anopheles fluviatilis</em></p>\n</td>\n<td>\n<p>Hilly areas and forests</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8045",
      "difficulty": "medium"
    },
    {
      "text": "Individuals with Duffy negative RBCs are resistant to:",
      "choices": [
        {
          "id": 1,
          "text": "P. vivax"
        },
        {
          "id": 2,
          "text": "P. malariae"
        },
        {
          "id": 3,
          "text": "P. ovale"
        },
        {
          "id": 4,
          "text": "P. falciparum"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>People with <strong>Duffy negative</strong> RBCs are <strong>resistant</strong> to <em><strong>P.vivax</strong></em>.</p>\n<p>Resistance to <strong><em>P.falciparum</em></strong>&nbsp;is seen in:</p>\n<ul>\n<li>Individuals with sickle cell trait&nbsp;</li>\n<li>Neonates, as fetal hemoglobin suppresses the development of <em><span class=\"s1\">P. </span><span class=\"s2\">falciparum</span></em></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8047",
      "difficulty": "medium"
    },
    {
      "text": "Which is the most sensitive index of recent transmission of malaria?",
      "choices": [
        {
          "id": 1,
          "text": "Spleen rate"
        },
        {
          "id": 2,
          "text": "Infant parasite rate"
        },
        {
          "id": 3,
          "text": "Parasite density index"
        },
        {
          "id": 4,
          "text": "Slide positivity rate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>infant parasite rate</strong> is regarded as the<strong> most sensitive </strong>index for recent transmission of <strong>malaria</strong> in a locality.</p>\n<p>It is defined as the <strong>%</strong> of <strong>infants</strong> showing <strong>malarial parasites</strong> in their<strong> blood films</strong>. The transmission of malaria is considered absent if the infant parasite rate is zero for 3 consecutive years in a locality (even though the Anopheline vectors responsible for the previous transmission may remain).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8049",
      "difficulty": "medium"
    },
    {
      "text": "In a town with a population of 1,00,000, a total of 50,000 slides were examined for malaria. Among these, 100 cases of malaria were confirmed. What is the annual parasite incidence of this town?",
      "choices": [
        {
          "id": 1,
          "text": "0.1"
        },
        {
          "id": 2,
          "text": "0.5"
        },
        {
          "id": 3,
          "text": "1"
        },
        {
          "id": 4,
          "text": "2"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The annual parasite incidence of this town (<strong>API</strong>) is<strong> 1</strong>.</p>\n<p>API =  Confirmed cases in a year</p>\n<p>  -----------------------------------   x 1000</p>\n<p>    Population under surveillance</p>\n<p>In this scenario, API = 100 x 1000/100000 = 1</p>\n<p>API is based on the number of <strong>slide-confirmed cases</strong> that are found through active and passive surveillance. It is a measure of <strong>malaria</strong> <strong>incidence</strong> in a community and helps in determining the burden of the disease.<strong> </strong>Areas with <strong>API ≥ 2 / 1000</strong> population are classified as <strong>high-risk areas</strong> and are eligible for <strong>vector</strong> <strong>control</strong>.</p>\n<p>Note: The number of slides examined is used to determine the annual blood examination rate (ABER).</p><hr><h3>Related Pearl: Malarial parameters</h3><p>Malarial parameters:</p>\n<table>\n<tbody>\n<tr>\n<td>Parameter</td>\n<td>Formula</td>\n</tr>\n<tr>\n<td>Annual Parasite Incidence</td>\n<td>\n<p>Confirmed cases in one year</p>\n<p>-----------------------------------&times;1000<br />Population under surveillance</p>\n</td>\n</tr>\n<tr>\n<td>Annual Blood Examination Rate</td>\n<td>\n<p>Number of slides examined</p>\n<p>-----------------------------------&times;100 <br />&nbsp; &nbsp; &nbsp; Population</p>\n</td>\n</tr>\n<tr>\n<td>Slide positivity Rate</td>\n<td>Percentage of slides found positive irrespective of species</td>\n</tr>\n<tr>\n<td>Slide Falciparum Rate</td>\n<td>Percentage of slides positive for <em>P. falciparum</em></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8051",
      "difficulty": "hard"
    },
    {
      "text": "Which parameter is used to measure the operational efficiency of the National Vector Borne Disease Control Programme?",
      "choices": [
        {
          "id": 1,
          "text": "Annual parasite index"
        },
        {
          "id": 2,
          "text": "Slide positivity rate"
        },
        {
          "id": 3,
          "text": "Annual falciparum incidence"
        },
        {
          "id": 4,
          "text": "Annual blood examination rate"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The annual blood examination rate (<strong>ABER</strong>)&nbsp;is used to measure the <strong>operational efficiency</strong> of the National Vector Borne Disease Control Programme&nbsp;(<strong>NVBDCP</strong>).</p><hr><h3>Related Pearl: Malarial parameters</h3><p>Malarial parameters:</p>\n<table>\n<tbody>\n<tr>\n<td>Parameter</td>\n<td>Formula</td>\n</tr>\n<tr>\n<td>Annual Parasite Incidence</td>\n<td>\n<p>Confirmed cases in one year</p>\n<p>-----------------------------------&times;1000<br />Population under surveillance</p>\n</td>\n</tr>\n<tr>\n<td>Annual Blood Examination Rate</td>\n<td>\n<p>Number of slides examined</p>\n<p>-----------------------------------&times;100 <br />&nbsp; &nbsp; &nbsp; Population</p>\n</td>\n</tr>\n<tr>\n<td>Slide positivity Rate</td>\n<td>Percentage of slides found positive irrespective of species</td>\n</tr>\n<tr>\n<td>Slide Falciparum Rate</td>\n<td>Percentage of slides positive for <em>P. falciparum</em></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8053",
      "difficulty": "medium"
    },
    {
      "text": "A 44-year-old woman from Assam presented with fever and chills recurring every 48 hours. On examination, she was conscious, oriented, and febrile. CBC, LFT, and RFT were normal. Peripheral smear revealed the following. What is the drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Quinine"
        },
        {
          "id": 2,
          "text": "Artesunate and sulphadoxine-pyrimethamine"
        },
        {
          "id": 3,
          "text": "Artemether and lumefantrine"
        },
        {
          "id": 4,
          "text": "Chloroquine and pyrimethamine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario and peripheral smear showing crescent-shaped gametocytes are suggestive of <strong>uncomplicated</strong>&nbsp;<strong>falciparum malaria</strong>. As this woman is from a <strong>North-Eastern state</strong>, the drug regimen of choice&nbsp;is <strong>ACT-AL</strong> (artemisinin combination therapy):&nbsp;</p>\n<ul>\n<li><strong>Artemether </strong>(20mg)</li>\n<li><strong>Lumefantrine </strong>(120mg) <strong>&nbsp;</strong></li>\n</ul>\n<p>This regimen is followed in the North-Eastern states of India due to documented resistance to<strong>&nbsp;</strong>sulphadoxine-pyrimethamine in these areas. ACT-AL is <strong>contraindicated</strong> in:</p>\n<ul>\n<li><strong>1<sup>st</sup> trimester</strong> of pregnancy</li>\n<li>Children&nbsp;<strong>&lt; 5 kg</strong></li>\n</ul><hr><h3>Related Pearl: Treatment of Malaria</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine</strong> 25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT/ Severe malaria </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Quinine </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong></p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st&nbsp;</sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>ACT:&nbsp;</strong>artemisinin-based combination therapy</p>\n<p><strong>AL:</strong>&nbsp;artemether-lumefantrine</p>\n<p><strong>SP</strong>: Sulfadoxine-<wbr />Pyrimethamine</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/39374e8ae8ff4766ab580e0847668af7.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8055",
      "difficulty": "easy"
    },
    {
      "text": "A 23-year-old pregnant woman at 11 weeks of gestation was diagnosed with falciparum malaria. What is the drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Quinine"
        },
        {
          "id": 2,
          "text": "Artemisinin-based combination therapy"
        },
        {
          "id": 3,
          "text": "Chloroquine"
        },
        {
          "id": 4,
          "text": "Primaquine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Quinine</strong> is the drug of choice for <strong>falciparum malaria</strong> during <strong>1st trimester</strong> of pregnancy.</p>\n<p>The treatment of falciparum malaria during pregnancy is as follows:</p>\n<ul>\n<li>1st trimester -&nbsp;quinine</li>\n<li><strong>2nd</strong> and <strong>3rd</strong>&nbsp;trimester -<strong>&nbsp;ACT-AL </strong>in North-Eastern states and <strong>ACT-SP </strong>in other states</li>\n</ul><hr><h3>Related Pearl: Treatment of Malaria</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine</strong> 25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT/ Severe malaria </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Quinine </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong></p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st&nbsp;</sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>ACT:&nbsp;</strong>artemisinin-based combination therapy</p>\n<p><strong>AL:</strong>&nbsp;artemether-lumefantrine</p>\n<p><strong>SP</strong>: Sulfadoxine-<wbr />Pyrimethamine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8061",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following patients with malaria can be treated with primaquine?",
      "choices": [
        {
          "id": 1,
          "text": "A 24-year-old pregnant woman at 30 weeks of gestation"
        },
        {
          "id": 2,
          "text": "A 10-year-old boy diagnosed with G6PD deficiency"
        },
        {
          "id": 3,
          "text": "A 40-year-old woman recently treated for a flare-up of SLE"
        },
        {
          "id": 4,
          "text": "A 60-year-old man who had a myocardial infarction 4 months ago"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Cardiac disease is not a contraindication for the use of <strong>primaquine</strong>. It&nbsp;is <strong>contraindicated</strong> in:</p>\n<ul>\n<li>Infants</li>\n<li><strong>Pregnant</strong> and lactating women</li>\n<li>Patients with<strong> G6PD deficiency</strong></li>\n<li>Patients at risk of developing&nbsp;<strong>granulocytopenia</strong>:\n<ul>\n<li>Systemic diseases including&nbsp;active RA and SLE</li>\n<li>Drugs&nbsp;that cause&nbsp;hemolysis or bone marrow&nbsp;depression&nbsp;</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8062",
      "difficulty": "medium"
    },
    {
      "text": "What is the dose of mefloquine given for chemoprophylaxis of malaria?",
      "choices": [
        {
          "id": 1,
          "text": "100 mg/week"
        },
        {
          "id": 2,
          "text": "200 mg /week"
        },
        {
          "id": 3,
          "text": "250 mg/week"
        },
        {
          "id": 4,
          "text": "300 mg/week"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Mefloquine</strong> <strong>250 mg</strong>&nbsp;weekly is given for&nbsp;chemoprophylaxis&nbsp;against malaria<strong>&nbsp;</strong>in&nbsp;<strong>adults.</strong>&nbsp;It should be administered <strong>2-3 weeks before</strong> travelling.&nbsp;</p>\n<p>Chemoprophylaxis is recommended for <strong>travellers</strong> from non-endemic areas and as a <strong>short term</strong> measure for <strong>soldiers</strong>, <strong>police</strong> and <strong>labour forces</strong> serving in highly endemic areas. It should be complemented by personal protection and vector control.</p>\n<p>&nbsp;The following drugs are used for malaria chemoprophylaxis:</p>\n<ul>\n<li><strong>Chloroquine -</strong>&nbsp;300 mg/week</li>\n<li><strong>Proguanil -</strong>&nbsp;200mg/day</li>\n<li>Mefloquine - 250mg/week</li>\n<li><strong>Doxycycline -</strong>&nbsp;100mg/day</li>\n</ul>\n<p>Mefloquine is contraindicated in cases with a history of convulsions, neuropsychiatric problems and cardiac conditions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8069",
      "difficulty": "medium"
    },
    {
      "text": "What is the most important strategy for the control of malaria in endemic areas?",
      "choices": [
        {
          "id": 1,
          "text": "Stratification of the problem"
        },
        {
          "id": 2,
          "text": "Chemoprophylaxis"
        },
        {
          "id": 3,
          "text": "Vector control"
        },
        {
          "id": 4,
          "text": "Avoiding relapses"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Vector control</strong> is the most important strategy to <strong>control malaria </strong>in<strong> endemic areas</strong>.&nbsp;Proper measures should be taken to kill both adult mosquitoes and larvae.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8072",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following was a component of the Roll back malaria programme?",
      "choices": [
        {
          "id": 1,
          "text": "IEC campaigns for community awareness"
        },
        {
          "id": 2,
          "text": "Insecticide treated bed nets"
        },
        {
          "id": 3,
          "text": "Development of larvivorous fish for eradication of larvae"
        },
        {
          "id": 4,
          "text": "Presumptive treatment of malaria"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Ensuring proper and expanded use of <strong>insecticide-treated mosquito nets&nbsp;</strong>was a component of the Roll Back Malaria (RBM) programme.</p>\n<p>The other components of the RBM initiative included:</p>\n<ul>\n<li>Strengthening the health system to ensure better <strong>delivery</strong> of <strong>health care</strong></li>\n<li>Ensuring adequate access to basic health care and <strong>training</strong> of health workers</li>\n<li>Encouraging the development of more effective and <strong>new</strong> <strong>anti-malaria</strong> <strong>drugs</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8073",
      "difficulty": "medium"
    },
    {
      "text": "Which sequence of infection poses the highest risk of dengue hemorrhagic fever?",
      "choices": [
        {
          "id": 1,
          "text": "DENV-1 --> DENV-2"
        },
        {
          "id": 2,
          "text": "DENV-3 --> DENV-2"
        },
        {
          "id": 3,
          "text": "DENV-4 --> DENV-2"
        },
        {
          "id": 4,
          "text": "DENV-1 --> DENV-3"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>DENV-1 --&gt; DENV-2 </strong>sequence of infection is associated with the <strong>highest&nbsp;risk</strong> of dengue hemorrhagic fever (DHF).</p>\n<p><strong>Multiple </strong>infections with<strong> different serotypes </strong>of the dengue virus lead to <strong>severe</strong> forms of dengue such as <strong>DHF/DSS.&nbsp;</strong>The first infection probably sensitizes the patient, while the second infection with a&nbsp;different serotype appears to produce immunological catastrophe.</p>\n<ul>\n<li>DENV-1 --&gt; DENV-2 - 500-fold risk (compared to primary infection alone)</li>\n<li>DENV-3 --&gt; DENV-2 - 150-fold risk</li>\n<li>DENV-4 --&gt; DENV-2 - 50-fold risk&nbsp;</li>\n</ul><p><strong>Dengvaxia</strong> is the WHO endorsed first-ever vaccine for dengue fever, effective against serotypes 1, 2, 3 and 4. It is currently licensed in 20 countries. It is approved for use in individuals <strong>9 - 16 years</strong> of age with laboratory-confirmed <strong>previous dengue</strong> infection (seropositive) and living in <strong>endemic areas</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8075",
      "difficulty": "medium"
    },
    {
      "text": "What is the extrinsic incubation period of the dengue virus?",
      "choices": [
        {
          "id": 1,
          "text": "1-2 days"
        },
        {
          "id": 2,
          "text": "4-6 days"
        },
        {
          "id": 3,
          "text": "8-10 days"
        },
        {
          "id": 4,
          "text": "12-14 days"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>&nbsp;The <strong>extrinsic incubation period</strong> of the dengue virus is&nbsp;<strong>8-10 days.&nbsp;</strong>This refers to the period necessary for the <strong>development</strong> of the disease agent in the <strong>arthropod host</strong>.&nbsp;</p>\n<p><em>Aedes</em> mosquitoes become infective when they feed on infected patients from <strong>1 day before onset</strong> of illness to the <strong>5th day</strong> (viremia stage) of illness. After 8-10 days of extrinsic incubation of the virus in a mosquito, <em>Aedes</em> becomes infective and can transmit the infection. <strong>Higher temperature</strong>&nbsp;results in <strong>shortening</strong> of the&nbsp;<strong>extrinsic incubation period</strong>, allowing mosquitoes to remain infectious for a longer duration.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8076",
      "difficulty": "medium"
    },
    {
      "text": "What is the cornerstone of treatment for a patient of dengue with warning signs?",
      "choices": [
        {
          "id": 1,
          "text": "IV Fluids"
        },
        {
          "id": 2,
          "text": "Platelets"
        },
        {
          "id": 3,
          "text": "Cryoglobulins"
        },
        {
          "id": 4,
          "text": "FFP"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>primary modality</strong> of treatment&nbsp;in patients with <strong>dengue</strong> with warning signs is <strong>IV fluids</strong>.</p>\n<p>The main pathology in dengue is <strong>plasma leakage</strong> resulting in intravascular volume depletion and thereby shock.<strong>&nbsp;Warning signs</strong> in dengue include:</p>\n<ul>\n<li>Abdominal pain or tenderness</li>\n<li>Persistent vomiting</li>\n<li>Clinical fluid accumulation (ascites, pleural effusion)</li>\n<li>Mucosal bleeding</li>\n<li>Lethargy or restlessness</li>\n<li>Hepatomegaly &gt;2 cm</li>\n<li>Increase in hematocrit concurrent with a rapid decrease in platelet count</li>\n</ul>\n<p><strong>Inpatient management</strong> is advised to all patients of dengue with warning signs. The management of dengue includes:</p>\n<ul>\n<li>IV <strong>crystalloids</strong>&nbsp;- mainstay of treatment</li>\n<li><strong>Platelet transfusion</strong> - severe thrombocytopenia (&lt;10,000/mm<sup>3</sup>) and active bleeding</li>\n</ul>\n<p>FFP and cryoglobulins are not the preferred for treatment in dengue.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7336",
      "difficulty": "medium"
    },
    {
      "text": "In patients with dengue fever, platelets should be transfused if the platelet count falls below which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "<50,000/cu.mm"
        },
        {
          "id": 2,
          "text": "<30,000/cu.mm"
        },
        {
          "id": 3,
          "text": "<20,000/cu.mm"
        },
        {
          "id": 4,
          "text": "<10,000/cu.mm"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Prophylactic platelet transfusion</strong> in dengue is to be initiated when the <strong>platelet count </strong>is <strong>&lt;10,000/cu.mm.</strong></p>\n<p>Indications for platelet transfusion in dengue are as follows:</p>\n<ul>\n<li>Platelet count &lt;10,000/cu.mm</li>\n<li>Prolonged shock with coagulopathy</li>\n<li>Systemic massive bleeding&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8078",
      "difficulty": "medium"
    },
    {
      "text": "When can a patient with dengue hemorrhagic shock be discharged?",
      "choices": [
        {
          "id": 1,
          "text": "No episode of fever for more than 24 hours with paracetamol"
        },
        {
          "id": 2,
          "text": "After the return of appetite"
        },
        {
          "id": 3,
          "text": "Urine output more than 200ml"
        },
        {
          "id": 4,
          "text": "After 24hrs from recovery of shock"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>A patient with <strong>dengue</strong> hemorrhagic shock can be <strong>discharged</strong> after<strong> </strong>the<strong> return of appetite. </strong></p>\n<p>Criteria for the discharge of patients recovering from dengue:</p>\n<ul>\n<li>Absence of fever for at least 24 hours without the use of antipyretic drugs</li>\n<li>Platelet count &gt;50,000/cu.mm</li>\n<li>Return of appetite</li>\n<li>Adequate urine output</li>\n<li>Visible clinical improvement</li>\n<li>Minimum of 2-3 days after recovery from shock</li>\n<li>No respiratory distress from pleural effusion or ascites</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7337",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a WHO-approved dengue vaccine for individuals seropositive for dengue virus?",
      "choices": [
        {
          "id": 1,
          "text": "Dengvaxia"
        },
        {
          "id": 2,
          "text": "DENVax"
        },
        {
          "id": 3,
          "text": "Tetravax -DV"
        },
        {
          "id": 4,
          "text": "TDENV PIV"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Dengvaxia</strong> is a WHO-approved vaccine for individuals <strong>seropositive</strong> for <strong>dengue</strong> virus. It is currently licensed in 20 countries.</p>\n<p>A pre-vaccination screening strategy must be adopted so that only dengue-seropositive individuals are vaccinated. It is indicated for individuals between <strong>9 to 16 years</strong>. It is given in 3 doses, 6 months apart. Booster doses are not required.</p>\n<p>However, it carries an increased <strong>risk</strong> of <strong>severe</strong> dengue in those who experience their <strong>first</strong> natural dengue infection <strong>after vaccination</strong> (seronegative individuals).</p>\n<p>Note: <strong>TV003</strong>, a live, attenuated, <strong>tetravalent dengue vaccine is</strong> currently in Phase-3 trials. It has shown <strong>efficacy</strong> in promoting immunity in both <strong>seropositive</strong> and <strong>seronegative</strong> individuals between <strong>2-59 </strong>years of age.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6634",
      "difficulty": "medium"
    },
    {
      "text": "The prepatent period in lymphatic filariasis is the time interval between:",
      "choices": [
        {
          "id": 1,
          "text": "Invasion of infective larvae and blockage of lymphatics"
        },
        {
          "id": 2,
          "text": "Inoculation of infective larvae and detection of microfilaria"
        },
        {
          "id": 3,
          "text": "Ingestion of microfilaria and development of third stage larva"
        },
        {
          "id": 4,
          "text": "Inoculation of infective larvae and maturation into adult worm"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> prepatent period </strong>in lymphatic filariasis is the time interval between <strong>inoculation</strong> of the infective larvae and the&nbsp;<strong>first appearance </strong>of<strong> detectable microfilaria</strong>.</p>\n<p>The <strong>clinical incubation</strong> period is the time interval from the&nbsp;<strong>invasion</strong> of infective larvae and the development of <strong>clinical</strong> manifestations. It is usually 8-16 months.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8082",
      "difficulty": "medium"
    },
    {
      "text": "A 44-year-old man presented with high-grade fever, chills, and pain in his groin area. Examination revealed reddish streaks over his lower limbs and bilateral non-pitting edema to the level of the knee. Swelling and tenderness in his scrotum was also noted. To diagnose the condition, when will you draw blood from the patient?",
      "choices": [
        {
          "id": 1,
          "text": "9 pm to 11 pm"
        },
        {
          "id": 2,
          "text": "2 am to 5 am"
        },
        {
          "id": 3,
          "text": "10 pm to 2 am"
        },
        {
          "id": 4,
          "text": "8 pm to 10 pm"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This patient has features of lymphangitis, lymphedema, and epididymo-orchitis, which are suggestive of&nbsp;<strong>acute filariasis</strong>.&nbsp;Blood must be drawn between <strong>10 pm&nbsp;to 2 am.</strong>&nbsp;This is because the maximum density of <strong>microfilaria </strong>are present in<strong>&nbsp;</strong>the peripheral<strong>&nbsp;blood</strong>&nbsp;at this time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8081",
      "difficulty": "medium"
    },
    {
      "text": "Which is the most sensitive method to detect low-density microfilaremia in blood?",
      "choices": [
        {
          "id": 1,
          "text": "Thick film"
        },
        {
          "id": 2,
          "text": "Thin film"
        },
        {
          "id": 3,
          "text": "Membrane filter concentration"
        },
        {
          "id": 4,
          "text": "DEC provocation test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most sensitive method to detect <strong>low-density</strong> microfilaremia in the blood is by&nbsp;<strong>membrane filter concentration.</strong></p>\n<p>The <strong>thick film</strong> is the most commonly used method for <strong>epidemiological assessment.&nbsp;</strong>The <strong>DEC provocative test</strong> is used to induce microfilaria to appear in the blood in the&nbsp;<strong>daytime</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8083",
      "difficulty": "hard"
    },
    {
      "text": "What is the dose of diethylcarbamazine for the treatment of Bancroftian filariasis?",
      "choices": [
        {
          "id": 1,
          "text": "3 mg/kg/d"
        },
        {
          "id": 2,
          "text": "6 mg/kg/d"
        },
        {
          "id": 3,
          "text": "8 mg/kg/d"
        },
        {
          "id": 4,
          "text": "10 mg/kg/d"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The dose of diethylcarbamazine (<strong>DEC</strong>) for treatment of Bancroftian <strong>filariasis</strong> is <strong>6 mg/kg/day </strong>orally for 12 days.</p>\n<p><strong>Medicated common</strong> <strong>salt</strong>&nbsp;with 1-4g DEC/kg is a special form of <strong>mass treatment,</strong> particularly in <strong>endemic areas.</strong>&nbsp;By this method, very low doses of DEC are given over a long period of time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8084",
      "difficulty": "medium"
    }
  ]
}